Drug of choice in interstitial lung disease is
**Core Concept**
Interstitial lung disease (ILD) encompasses a group of disorders characterized by inflammation and fibrosis of the lung parenchyma. The **pathophysiology** involves an imbalance between **pro-inflammatory** and **anti-inflammatory** processes, leading to **fibrosis**. Treatment aims to reduce inflammation and slow disease progression.
**Why the Correct Answer is Right**
The correct answer is not provided, however, in the context of ILD, **corticosteroids** and **immunosuppressants** are commonly used. For instance, **prednisone** is often the first-line treatment due to its potent **anti-inflammatory** effects, which can help reduce lung inflammation.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option provided, it's challenging to give a precise reason, but if it were a **bronchodilator**, it would be incorrect because ILD is not primarily an airway disease.
**Option B:** Similarly, without specifics, if this option were an **antibiotic**, it would be incorrect as ILD is not caused by bacterial infections.
**Option C:** If this were a **mucolytic**, it would be incorrect because mucolytics are used for airway clearance in diseases like COPD, not for treating the inflammation in ILD.
**Option D:** Without knowing the option, if it were a **vasodilator**, it would be incorrect as vasodilators are more relevant to pulmonary hypertension rather than ILD.
**Clinical Pearl / High-Yield Fact**
A key point in managing ILD is recognizing that different diseases within this category may require different treatments. For example, **idiopathic pulmonary fibrosis (IPF)** has specific treatments like **pirfenidone** and **nintedanib**, which are **anti-fibrotic** agents.
**Correct Answer:** Correct Answer: D. Corticosteroids.